Fragment‐based drug discovery (FBDD) is a crucial strategy for develo** new drugs that
have been applied to diverse targets, from neglected infectious diseases to cancer. With at …

Tuberculosis remains one of the world's leading infectious disease killers, causing more
than 1.5 million of deaths each year. It is therefore a priority to discover and develop new …

Two series of quinazolinone derivatives were designed and synthesized as dihydrofolate
reductase (DHFR) inhibitors. All compounds were evaluated for their antibacterial and …

The L-arginine biosynthesis pathway consists of eight enzymes that catalyse the conversion
of L-glutamate to L-arginine. Arginine auxotrophs (argB/argF deletion mutants) of …

Antibiotic-resistant infections are a pressing global concern, causing millions of deaths each
year. Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of nosocomial …

Dihydrofolate reductase (DHFR) is an important drug target and a highly studied model
protein for understanding enzyme dynamics. DHFR's crucial role in folate synthesis renders …

Nontuberculous mycobacteria (NTM) are emerging human pathogens linked to severe
pulmonary diseases. Current treatments involve the prolonged use of multiple drugs and are …

Abstract mtbDHFR‐targeting inhibition has become a promising approach for tuberculosis
treatment. In the current research, a multi‐step virtual screening effort toward ZINC and MCE …

The high lethality of Staphylococcus aureus infections and the emergence of antibiotic
resistance make the development of new antibiotics urgent. Our previous work identified a …

Tuberculosis (TB) is an obstinate and infectious disease requiring a relatively longer
treatment duration than other bacterial infections. The current treatment regime is prolonged …